INTRODUCTION
The Florida puma (Puma concolor coryi) is an endangered subspecies whose range was contiguous with other puma populations (Young and Goldman, 1946) . By the late 20th century, however, habitat destruction, exploitation, and human population growth had reduced the Florida puma population to an isolated remnant numbering an estimated 20 to 30 individuals (Nowak and McBride, 1974) . With protection and management, including the translocation of eight pumas (Puma concolor couguar) from Texas in 1995 as part of a genetic restoration program (Seal, 1994) , the population rebounded to at least 87 by 2003 (McBride, 2003 . Consequently, this greater density may have increased both exposure to domestic animals and the risks of infectious disease transmission. Herein, we describe an epizootic of feline leukemia virus (FeLV) and its management in the free-ranging Florida puma population.
Feline leukemia virus is a retrovirus of domestic cats (Felis silvestris catus). In Florida, the prevalence of antigenemia among feral cats is ,4% (Lee et al., 2002) . Transmission is usually by direct contact, and outcome after exposure depends on several host and viral factors. Most infections are self-limiting in domestic cats, being eliminated shortly after exposure (regressive infection) or progressing to latent infections before containment (Har-dy, 1980; Torres et al., 2005) . Although domestic cats developing regressive or latent infections may be transiently viremic postexposure, they are not considered important to the maintenance of the disease in domestic cats. In approximately one third of exposed cats, viremia is persistent and eventually results in clinical syndromes of immunosuppression, anemia, neoplasia, or a combination. Mortality among persistently infected domestic cats is approximately fivefold that of uninfected cats, and 83% die within 3.5 yr (McClelland et al., 1980) . Feline leukemia virus in nondomestic felids is rare. Reported infections in captive nondomestic felids include a leopard cat (Felis bengalensis) (Rasheed and Gardner, 1981) , puma (Meric, 1984) , clouded leopard (Neofelis nebulosa) (Citino, 1986) , bobcat (Lynx rufus) (Sleeman et al., 2001) , and several cheetahs (Acinonyx jubatus) (Briggs and Ott, 1986; Marker et al., 2003) . Despite extensive testing for FeLV in free-ranging felid populations, published reports of FeLV infections in the wild have been limited to three pumas (P. concolor) (Rickard and Foreyt, 1992; Jessup et al., 1993 ) and a sand cat (Felis margarita) (Ostrowski et al., 2003) . Ten to 24% of European wildcats (Felis silvestris silvestris) also were FeLV antigen positive (Daniels et al., 1999; Fromont et al., 2000) , although interbreeding with domestic cats occurs in this subspecies frequently (French et al., 1988) . Most infections in nondomestic felids were self-limiting. In a survey of North American zoos, seven of 11 (64%) nondomestic felids that tested FeLV positive initially were negative when retested. The remaining four felids were not retested, and they did not develop clinical signs of FeLV (Kennedy-Stoskopf, 1999) . Persistent infections were seen in a free-ranging and a captive puma, a bobcat, and cheetahs, and clinical pathology and necropsy findings included anemia, lymphopenia, other cytopenias, lymphadenopathy, septicemia, opportunistic infections, and lymphoma (Meric, 1984; Briggs and Ott, 1986; Jessup et al., 1993; Sleeman et al., 2001) .
Management of FeLV in domestic cat populations includes vaccination, test-removal, or both. Inactivated whole-virus vaccines require an initial (prime) inoculation followed by booster in 3-6 wk. In challenge studies, whole-virus vaccines such as Fel-O-Vax LvkH and Fevaxyn FeLVH provided from 86 to 100% protection (reviewed by Sparkes, 1997; Torres et al., 2005) ; however, protection after a single inoculation is likely low. Few studies have examined duration of immunity beyond 1 yr, although a recombinant FeLV vaccine was shown to be protective over 3 yr (Hofmann-Lehmann et al., 1995) . Vaccination has been used to prevent FeLV in captive nondomestic felids; however, to our knowledge FeLV vaccination of free-ranging nondomestic felids has not been reported.
In Florida pumas, routine FeLV enzymelinked immunosorbent assay (ELISA) antigen testing was negative between 1978 and November 2002 (Roelke et al., 1993; Florida Fish and Wildlife Conservation Commission [FWC] , unpubl. data); however, during the 2002-2003 capture season, two pumas tested antigen positive. These findings led to an investigation of FeLV in the puma population and efforts to manage the epizootic.
MATERIALS AND METHODS

Florida puma capture, handling, and necropsy
Free-ranging pumas were captured by the FWC and National Park Service (NPS) between 1 July 2000 and 1 April 2007 in southern peninsular Florida (south of 28uN) as described by McCown et al. (1990) and McBride and McBride (2007) . Pumas were immobilized with ketamine HCl (Congaree Veterinary Pharmacy, Cayce, South Carolina, USA) combined with a-2 agonists tiletamine HCl/zolazepam HCl (TelazolH, Fort Dodge Animal Health [FDAH] , Fort Dodge, Iowa, USA), midazolam HCl (Abbott Laboratories, North Chicago, Illinois, USA), or both. All animals underwent physical examination. Ap-proximately 70-140 ml of blood was collected in serum separator, ethylenediaminetetraacetic acid (EDTA), Na-heparin, and ACD blood tubes (BD Biosciences, Franklin Lakes, New Jersey, USA). Blood smears were made from whole blood at capture or with EDTA whole blood approximately 6-24 hr after collection. Puma ages were either known (handled as neonates), or they were estimated from tooth wear and gum line recession. Neonates were handled as described by Land et al. (1998) .
Pumas .4 mo old were vaccinated subcutaneously against feline viral rhinotracheitis, feline calicivirus, feline panleukopenia virus (Fel-O- (blood, urine, and aqueous humor) were collected at necropsy. Blood was centrifuged at 2,000 rpm for 10 min, and the supernatant was decanted. Representative tissues were placed in 10% neutral buffered formalin. Fixed tissues were embedded in paraffin, sectioned at 5-6 mm, and stained with hematoxylin and eosin. All tissues not analyzed immediately were archived at 220 or 270 C.
Diagnostics
Feline leukemia virus ELISA antibody optical densities (ODs) were performed at Hansen Veterinary Immunology (Dixon, California, USA) using techniques described by Lutz et al. (1980) ; ODs of ,0.25 were considered negative, 0.25 to ,0.35 were low positive, 0.35 to ,0.5 were medium positive, and $0.500 were high positive. For statistical analyses, ODs $0.25 were considered positive. Antigen ELISAs (ViraCHEKH FeLV, Synbiotics Animal Health, San Diego, California, USA) were performed at the New York State Diagnostic Laboratory (Cornell University, Ithaca, New York, USA). Adsorbing reagents were used to remove heterophile antibody. Beginning November 2003, EDTA whole blood from captured pumas was tested in the field using a rapid immunochromatic assay (SNAP Combo, IDEXX Laboratories, Westbrook, Maine, USA). The SNAP Combo also was used to test fluids collected from necropsied pumas, including blood collected from the thoracic cavity, heart, vessels, and marrow cavity, and aqueous humor. Blood smears from ELISA antigen-positive pumas were also tested by immunofluorescence assay (IFA) at the National Veterinary Laboratory (Franklin Lakes, New Jersey, USA) using techniques described by Hardy et al. (1973) .
Conventional polymerase chain reaction (PCR) to detect provirus was performed at the Laboratory of Genomic Diversity (National Cancer Institute [NCI] , Frederick, Maryland, USA) on tissues collected from pumas at capture and necropsy. Methods and results are described by Brown et al. (2008) . Viral isolation and subgroup analysis were performed at the Center for Retrovirus Research (The Ohio State University, Columbus, Ohio, USA). Plasma from Florida Puma (FP) 109 and FP115 was inoculated directly onto HT1080 (human fibroblastoid), H927 (feline fibroblastoid), FEA (feline fibroblastoid), and primary feline peripheral blood mononuclear cells (PBMCs) and tested by ELISA SNAP at 2 and 4 wk. Peripheral blood mononuclear cells from FP123 and FP122 were cultured in lymphocyte medium (RPMI 1640 medium with 10% fetal bovine serum, 1 mM Lglutamine, and antibiotics) with 7 mg/ml concanavalin A and 20 U/ml interleukin-2. The inoculated cells then were cocultured with 3201 (feline lymphoblastoid), Molt 4 (human lymphoblastoid), and domestic cat PBMCs. Cultures were tested weekly for FeLV p27 by ELISA.
Pumas were tested for feline immunodeficiency virus (FIV) antibodies by Western blot using Petaluma antigen (New York State Diagnostic Laboratory), a three-antigen (fca, pco, and ple) chemiluminescence method described by Troyer et al. (2005) , or both.
Criteria for defining outcomes after exposure Possible outcomes after exposure to FeLV in pumas were classified as regressive, latent, or persistent infections based on test results, duration of antigenemia, and presence of clinical disease. Pumas with previous regres-sive infections had a positive ELISA antibody OD, but they were PCR and ELISA antigen negative. Latently infected pumas retained provirus in leukocytes at a level sufficient to be detectable by conventional PCR, but they were ELISA antigen negative. Persistently infected pumas were ELISA antigen positive and were IFA positive, were antigenemic for $16 wk, and/or developed FeLV-related diseases.
Statistics
Proportion of pumas positive for FeLV antibodies was calculated as the percentage with ELISA ODs .0.25. Three binary categorical predictors were considered: gender, FIV status, and location (north or south of Interstate highway 75 [ca. 28.05uN]) (Fig. 1) . Two predictors were treated as continuous variables: age (in months/12) and sample date (in days/365.25 since 1 January 1960). Logistic regression using EgretH software (Cytel Software Corporation, Cambridge, Massachusetts, USA) was performed to investigate ELISA antibody status as a binary response variable. Odds ratios and their 95% confidence limits were calculated for one state of the binary predictors in comparison with the other state. For the continuous predictors, the odds ratios represented the change in odds of positive FeLV per unit change in the predictor. Significant (P,0.05) difference from 1.0 was determined for the odds ratios by the Wald test. To account for correlation among replicate outcomes from individuals with multiple test results, puma identity was modeled as a random effect within the logistic regression model and evaluated by a likelihood ratio test. Significant predictors emerging from univariate analyses (location and date) showed no significant interaction. Odds ratios are presented from a bivariate logistic model, with location and date as additive predictors.
Vaccine trial
While in captivity at White Oak Conservation Center (WOCC, Yulee, Florida, USA), three Florida pumas and three Texas pumas were vaccinated against FeLV, monitored for adverse reactions, and sampled for antibody response. Texas pumas were females approximately 10 yr old, and they were removed from the wild after completion of a genetic restoration project. Florida pumas were in captivity after being orphaned (FP113 and FP114 were siblings). Kittens (one male, two females) were 1 to 1.25 yr old when vaccinated. Pumas were chemically immobilized, examined, sampled, and primed with Fel-OVax LvK (2 ml IM); the procedure was repeated 3-6 wk later. FeLV ELISA antibody ODs were determined for serum collected at initial inoculation (all pumas), booster (all pumas), and 15 days after the first booster (Texas pumas). Pumas were not challenged with live FeLV. Two adult pumas were similarly primed and boosted with FevaxynFeLV while in captivity recovering from injuries. These pumas were monitored for adverse reactions, but FeLV antibody ODs were not determined. The vaccine trial was approved by the WOCC Institutional Animal Care and Use Committee.
RESULTS
Diagnostics
Results of FeLV diagnostics and putative classification of FeLV infections in Florida pumas are presented in Table 1 (Fig. 1) . The probability of having a positive antibody OD was not affected significantly by age, gender, or FIV status for the complete data set or whether analysis was limited to pumas sampled north of Interstate highway 75 and after the suspected onset of the epizootic (2001 and beyond). Of pumas sampled on multiple occasions, six had positive ODs initially, but they were negative when resampled 9 mo to 3 yr later (Table 1) .
Before July 2000, all pumas sampled (117 individuals sampled on 256 occasions) were ELISA antigen negative based on published (Roelke et al., 1993) and unpublished data (FWC) and retrospec-tive testing. During the study period, 142 pumas were tested on 225 occasions for FeLV antigen by ELISA; the proportion of antigenemic (viremic) pumas $3 mo of age, not vaccinated previously for FeLV, and sampled during the study period, was 4% (5/131). All viremic pumas were captured in OKS, and they had overlapping home ranges. The proportion of pumas with viremia in OKS (Fig. 1) during the outbreak (approximately January 2001 to June 2005) was 46% (5 of 11). Average age of viremic pumas (three males, two females) was 4.85 yr (SD 63.5, range 2.25-11 yr). FeLV antigen was detected by SNAP test in thoracic, splenic, and venous blood, and aqueous humor collected from viremic pumas at necropsy, even in severely autolyzed carcasses. Feline leukemia virus was cultured from four viremic pumas (FP132 was not cultured). Of the human and feline cell lines inoculated, only primary domestic cat PBMCs, Molt 4 cells, and 3201 feline lymphoid cells became positive at 1-2 wk and remained positive for 4 wk. These cell lines had continuous production of FeLV p27 as well as significant giant cell formation (Molt 4 cells) and cell death (3201 cells). Negative cultures were maintained for up to 6 wk. Growth in feline cells was consistent with subgroup A virus. The ability of the sample from FP122 to grow in human cells (which would have indicated the presence of subgroup B, C, or both in addition to subgroup A) may be an artifact due to prior coculture of the puma cells with domestic cat PBMCs.
During the study period, 47% of pumas tested were positive for FIV antibodies by Western blot, ELISA, or both. Three of five (60%) FeLV antigen-positive pumas also tested positive for FIV.
Clinical findings
Physical exam, selected complete blood count parameters, and significant necropsy findings for viremic pumas are listed in Table 2 . Suspected causes of death for the five viremic pumas were septicemia (n52), intraspecific aggression (n52), and anemia/dehydration (n51). Time from first antigen-positive sample collection to death averaged 9.25 wk (SD 610.3, range 2-24.6 wk) in pumas viremic at capture (FP109, FP115, FP122, and FP123). Time from suspected exposure to death for one puma (FP132) was 18 wk. The case-fatality rate for pumas with evidence of exposure to FeLV was 13% (3/23 exposed [positive for FeLV antibodies]) to 22% (5/23) depending on the inclusion or exclusion respectively of two viremic pumas dying from intraspecific aggression. This rate, however, may be altered artificially because of false positives or failure of some exposed pumas to generate, or maintain, antibody levels sufficient to test positive by ELISA.
Vaccination
During the vaccine trial, no adverse reactions were observed after initial inoculation or booster, and most pumas developed an antibody response. On 20 August 2003, the three vaccine trial Florida pumas were released into the 
DISCUSSION
We investigated and managed an epizootic of FeLV in free-ranging Florida pumas. Diagnostic tests developed for use in domestic cats were used to diagnose and help infer the pathogenesis of the disease. Although diagnostic tests validated for domestic animals but used on wildlife must be interpreted with caution (Hietala and Gardner, 1999) , the test results in this study were consistent biologically and seemed to be suitable for use in pumas.
The outcome in pumas after exposure to FeLV seems to be similar to that in domestic cats, with pumas showing evidence of regressive, latent, or persistent infections (Table 1) . These classifications serve to simplify and categorize our results; in reality, FeLV exposure more likely results in a continuum of possible outcomes from failure of viral replication to persistent infection and death (Torres et al., 2005) . Furthermore, premature deaths, severe autolysis, limitations of diagnostic tests, and limited ability to resample pumas while living precluded complete determination of disease progression in all cases. Based on positive ELISA antibody ODs but antigen-and PCR-negative test results, many pumas exposed to the virus are able to clear the infection. Assuming a similar pathogenesis Complete blood counts and serum biochemistry parameters were determined by AntechH Diagnostics (Smyrna, Georgia, USA). Blood smears were examined at the University of Florida College of Veterinary Medicine for hemoparasites, white blood cell differential counts, and red blood cell morphology. Necropsied pumas were tested for rabies virus by direct fluorescent antibody at the Jacksonville Central Laboratory (Jacksonville, Florida, USA). Viral isolation and real-time and conventional PCR for canine distemper virus, pseudorabies virus, flaviviruses, and alphaviruses were performed at the Southeastern Cooperative Wildlife Disease Study (Athens, Georgia, USA) on brain, heart, and other tissues collected from pumas dying of unknown causes. in domestic cats, pumas in this category would have cleared the infection within weeks to months of exposure. The majority of domestic cats in this category are considered refractory to reinfection (Charreyre and Pedersen, 1991) . Puma FP109 may have had a regressive infection when captured in January 2003; at capture, he was anemic, lymphopenic, and had peripheral lymphadenopathy. Levy (1999) and Citino (1986) described similar signs in domestic cats and a clouded leopard, respectively, with transient viremias. Puma FP109 also had a high ELISA antibody OD. Antibodies detectable by ELISA occur shortly after infection in domestic cats (Lutz et al., 1980) , and high antibody ODs in domestic cats are a good prognostic indicator for recovery (Hofmann-Lehmann et al., 2001) . Poor carcass quality and an inconclusive FeLV IFA precluded further assessment of FP109's FeLV status. Pumas classified as latently infected presumably failed to control viral replication until later in the course of infection. Based on telemetry data (FWC, unpubl. data), at least one female (FP110) with evidence of a latent infection survived exposure to at least two FeLV-positive males without developing persistent viremia. This female continues to survive, reproduce, and remain nonantigenemic almost 5 yr after diagnosis. No latently infected pumas are known to have progressed to a persistent infection.
Persistent infections were diagnosed in four pumas of which three were thought to have had FeLV-related disease conditions. Persistently infected pumas had relatively low antibody ODs, suggesting a muted humoral response to infection. In domestic cats, low ELISA antibody ODs are characteristic of persistent infections (Hofmann-Lehmann et al., 2001) . Nonneoplastic diseases, including secondary infections and anemia, were most commonly associated with FeLV infection in domestic cats (Reinacher, 1989) . Septicemia, resulting from opportunistic bacterial infections, is thought to have killed two FeLV-infected pumas (FP115 and FP132). Nonregenerative anemias were seen in FP109 and FP122 when captured and may have been the cause of death in FP122. Progression of clinical disease seemed to be rapid in persistently infected pumas. Although 50% of viremic domestic cats die within 6 mo of diagnosis (Jarrett, 1983) , adult cats experience a longer induction period and less severe disease compared with younger age groups (Hoover et al., 1976) . All viremic pumas were adults, and although the time of infection is unknown in most infected pumas, the average time from positive sample collection to mortality was just over 9 wk. Lack of supportive care (as in captive or domestic cats) and presumably increased exposure to pathogens may play a role in this apparently more rapid clinical course.
In domestic cats, the most significant factor affecting outcome after exposure is thought to be host age (Hoover et al., 1976) , although genotype, immunocompetence, coinfection with FIV, route of exposure, virus burden, and strain of virus also may be important (Hoover et al., 1980; Grindem et al., 1989; Hoover and Mullins, 1991; Rojko and Kociba, 1991) . Nevertheless, the factors affecting the outcome after exposure to FeLV in domestic cats remain largely unknown (Hofmann-Lehmann et al., 2001) . With the average age of viremic pumas approaching 5 yr, maturity did not seem to protect against infection. In addition, genetic variation (based on expected heterozygosity [H e ] at selected microsatellite DNA loci; Roelke, unpubl. data) within the puma population did not seem to influence significantly the outcome after exposure. Although some infected pumas had very low genetic variation (likely the result of inbreeding and genetic drift), at least two had H e values much greater than the average for the population. Similarly, ancestral admixture did not seem to play a role because both intergrade and canonical Florida pumas developed FeLV and clinical disease (Brown et al., 2008; Johnson, unpubl. data) . Both retroviruses (FIV and FeLV) have overlapping host cell tropism. In domestic cats, coinfection with FIV results in synergism of immunosuppression and severe clinical disease (Pedersen et al., 1990) . The effect of pre-existing FIV infection in Florida pumas is unknown; however, some FIVinfected pumas were capable of resisting persistent infection after FeLV exposure. Conversely, persistent FeLV infections occurred in the absence of FIV infection. Finally, the pathogenicity of the FeLV strain infecting pumas may play a role in the apparent greater impact of FeLV on pumas. Based on genotyping, the strain isolated from pumas seems to be related to a virulent domestic cat strain (Brown et al., 2008) .
The source of infection in pumas is unknown; however, in reports of FeLV infection in nondomestic felids, the authors speculated or provided direct evidence that infected domestic cats were the source. Kennedy-Stoskopf (1999) specu-lated that consumption of FeLV-infected domestic cats by nondomestic felids would be an effective way to transmit the virus, and domestic cat remains have been found in the stomachs of necropsied pumas from California (Jessup et al., 1993) and in two Florida pumas. Exposure of Florida pumas to domestic cats may be increasing as growing puma and human populations expand the urban-wildland interface. The transmission of FeLV from a domestic cat to a puma is probably a rare event, but once the species barrier was crossed, the virus was likely spread puma to puma. In domestic cats, prolonged exposure usually is necessary for transmission; however, we suspect that FP132 was infected after an aggressive encounter with a viremic puma (FP123). Although FP132 was FeLV antigen negative when handled 1-2 days after the suspected encounter, he developed persistent FeLV infection and died within 5 mo. It is also possible that FP132 was infected after capture or was exposed before the encounter with FP123 but was not yet viremic. Although FeLV is present in the semen of domestic cats, venereal transmission is not considered important (Hoover and Mullins, 1991) . Nevertheless, the presence of infection in female pumas suggests that transmission also may occur during courtship and mating. Higher puma densities may facilitate puma-topuma transmission. The population has more than tripled since the early 1990s (McBride, unpubl. data), whereas puma habitat has been reduced.
Based on ELISA antibodies, PCR results, and viral sequencing (Brown et al., 2008) (Fromont et al., 1998) , and 5) some pumas were vaccinated against FeLV.
Because of the unprecedented nature of this epizootic and serologic evidence of significant exposure without persistent infection, management of FeLV in the puma population was conservative initially. Few reported adverse effects in FeLVvaccinated captive nondomestic felids combined with the results of the vaccine trial indicated FeLV vaccination was safe for free-ranging pumas; however, the efficacy of vaccination in free-ranging nondomestic felids is unknown. In domestic cats, inactivated whole-virus FeLV vaccines can be highly effective, although the need for boosters limits their usefulness in free-ranging populations. Management of FeLV in free-ranging pumas began in August 2003 with the release of three vaccinated subadults used in the vaccine trial. Thereafter, free-ranging pumas were primed at capture, and depend-ing on FeLV risk, some were boosted by dart or at recapture. Assuming a minimum population size of 87 (McBride, 2003) , the largest percentage of the living population receiving at least one inoculation during the epizootic was 23% (from 9 April to 28 July 2004); the largest percentage primed and boosted was 13% (same time period). Using computer models, Lubkin et al. (1996) estimated that from 23% to 72% of a closed domestic cat population with a FeLV prevalence of 10% must be vaccinated effectively each year to eliminate infection. Because vaccination efforts targeted the northern portion of puma range, the percentage vaccinated in these areas was likely much greater (Fig. 3) . Haydon et al. (2006) used modeling to demonstrate that the impact of infectious disease outbreaks on endangered populations can be curtailed by concentrating vaccinations in habitat corridors. This targeted vaccination can be enhanced by concurrently vaccinating the core population. A similar strategy was used for pumas; vaccinations were concentrated initially in a band between OKS and the remainder of the population, followed by vaccination throughout their range. Test-removal of infected individuals, although proven to be beneficial in closed domestic cat populations, initially was not part of FeLV management in pumas because of perceived risks for social structure disruption and increased intraspecific aggression. Nevertheless, test-removal is now included in the Florida puma FeLV management plan.
Historically, the lack of antigen-positive animals and absence of clustered FeLV cases suggested that FeLV was not maintained in free-ranging nondomestic felid populations (Kennedy-Stoskopf, 1999) . The finding, however, of five viremic pumas over 2 yr suggests that the virus had, at least temporarily, become established in the puma population. Florida pumas consist of a single small population; thus, they are at greater risk for extinction resulting from a catastrophic disease epizootic (Beier et al., 2003) . Therefore, Florida pumas should continue to be monitored for and vaccinated against FeLV, and new epizootics should be managed aggressively. Managers of other free-ranging nondomestic felid populations similarly should monitor for FeLV antigen and consider vaccination, testremoval, or both should FeLV be introduced.
